Editing Paclitaxel (section)

== Society and culture ==

=== Legal status ===
Paclitaxel was approved for medical use in the European Union in 2008.<ref name="Naveruclif EPAR" />

In November 2023, the [[Committee for Medicinal Products for Human Use]] (CHMP) of the [[European Medicines Agency]] adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Naveruclif, intended for the treatment of metastatic breast cancer, metastatic adenocarcinoma of the pancreas and non-small cell lung cancer.<ref name="Naveruclif EPAR" /> The applicant for this medicinal product is Accord Healthcare S.L.U.<ref name="Naveruclif EPAR">{{cite web | title=Naveruclif EPAR | website=[[European Medicines Agency]] (EMA) | date=9 November 2023 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/naveruclif | access-date=28 December 2023}} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref> Naveruclif was approved for medical use in the European Union in January 2024.<ref name="Naveruclif EPAR" /><ref name="Naveruclif PI" />

In May 2024, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Apexelsin, intended for the treatment of metastatic breast cancer, metastatic adenocarcinoma of the pancreas and non-small cell lung cancer.<ref name="Apexelsin EPAR" /> The applicant for this medicinal product is WhiteOak Pharmaceutical B.V.<ref name="Apexelsin EPAR">{{cite web | title=Apexelsin EPAR | website=European Medicines Agency | date=30 May 2024 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/apexelsin | access-date=31 May 2024}} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref> Apexelsin was approved for medical use in the European Union in July 2024.<ref name="Apexelsin EPAR" /><ref name="Apexelsin PI" />

=== Economics ===
{{as of|2006}}, the cost to the NHS per patient in early breast cancer, assuming four cycles of treatment, was about £4,000 (approx. $6,000).<ref>{{cite web|title=NICE Guidance TA108|date=27 September 2006 |url=http://guidance.nice.org.uk/TA108/guidance/pdf/English|url-status=live|archive-url=https://web.archive.org/web/20070630182944/http://guidance.nice.org.uk/TA108/guidance/pdf/English|archive-date=30 June 2007}}</ref>